Norges Bank’s Design Therapeutics DSGN Stock Holding History

Norges Bank’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$3.23M	–	2087
2022 Q1	$3.23M	Hold	200,000	–	–	﹤0.01%	1924
2021 Q4	$4.28M	Hold	200,000	–	–	﹤0.01%	1930
2021 Q3	$2.94M	Hold	200,000	–	–	﹤0.01%	1996
2021 Q2	$3.98M	Hold	200,000	–	–	﹤0.01%	1938
2021 Q1	$5.98M	Buy	+200,000	New	+$6.75M	﹤0.01%	1884

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank's DSGN Position: Q2 2022 in Review

Norges Bank sold out of Design Therapeutics (DSGN) in Q2 2022, closing a stake of 200,000 shares — an estimated $3.23M sold.

Norges Bank first reported a position in DSGN in Q1 2021 and held it in 5 quarters. The position peaked at $5.98M in Q1 2021. 74 funds tracked by Wall St. Rank hold DSGN as of Q2 2022.

Norges Bank reported no remaining Design Therapeutics position as of Q2 2022 after selling out during the quarter.
Norges Bank sold 200,000 Design Therapeutics shares in Q2 2022, an estimated $3.23M.
Norges Bank first reported a position in Design Therapeutics in Q1 2021 and held it in 5 quarters.
Norges Bank's Design Therapeutics position peaked at $5.98M in Q1 2021.
74 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.